Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A 3'UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1.

Molecular cancer - 26 Apr 2014

Akdeli Neval, Riemann Kathrin, Westphal Jana, Hess Jochen, Siffert Winfried, Bachmann Hagen S

Abstract excerpt

BACKGROUND: The Polo-like Kinase 1 (PLK1) protein regulates cell cycle progression and is overexpressed in many malignant tissues. Overexpression is associated with poor prognosis in several cancer entities, whereby expression of PLK1 shows high inter-individual variability. Although PLK1 is extensively studied, not much is known about the genetic variability of the PLK1 gene. The function of PLK1 and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3' Untranslated Regions
Share to 5' Untranslated Regions

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Luciferases

Share to Nucleic Acid Conformation

Share to Open Reading Frames

Share to Polo-Like Kinase 1

Share to RNA Stability

Share to Silencer Elements, Transcriptional

Source

Open in PubMed Open full text

Identifiers

PMID: 24767679
DOI: 10.1186/1476-4598-13-87
PMCID: PMC4020576

Genes

PLK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A 3'UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1.PMID 24767679Read ↗

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implicationsSemantic proximity Read ↗

Present and Future Perspective on PLK1 Inhibition in Cancer TreatmentSemantic proximity Read ↗

The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor MetastasisSemantic proximity Read ↗

PLK-1 Targeted Inhibitors and Their Potential against TumorigenesisSemantic proximity Read ↗

The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?Semantic proximity Read ↗

From Plk1 to Plk5Semantic proximity Read ↗

Thoughts on the current assessment of Polo-like kinase inhibitor drug discoverySemantic proximity Read ↗

The Role of Polo-like Kinase 1 in Carcinogenesis: Cause or Consequence?Semantic proximity Read ↗

Down-regulated and Commonly mutated ALPK1 in Lung and Colorectal Cancers.Semantic proximity Read ↗

The balance of Polo-like kinase 1 in tumorigenesisSemantic proximity Read ↗

Germline variation in the 3'-untranslated region of the POU2AF1 gene is associated with susceptibility to lymphoma.Semantic proximity Read ↗

Epigenetic Inactivation Implies a Tumor Suppressor Function in Hematologic Malignancies for Polo-Like Kinase 2 but not Polo-Like Kinase 3Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.